

April 26, 2019

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Announces Revision to its Dividend Forecast for the Year Ending March 2019

Sumitomo Dainippon Pharma Co., Ltd. (hereinafter referred to as the “Company”) announced today that it has revised its dividend forecast for the year ending March 31, 2019 (FY2018), as indicated below.

1. Reasons for the Revision

The allocation of the Company’s profits in a customarily appropriate manner to its shareholders is one of the Company’s fundamental management policies.

The Company believes it important to distribute surplus in an appropriate manner reflecting any improvement in its performance. Accordingly, a performance-linked dividend hike will be considered in addition to consistent dividend payments. In a constant effort to further increase its corporate value, the Company remains committed to establishing a solid management base and a strong financial position, while making proactive investments for sustainable business growth. In the Mid-term Business Plan covering the period from fiscal 2018 through 2022, the Company aims for a five-year average dividend payout ratio of 20% or higher during the period.

During the fiscal year ending March 31, 2019, the Company expects core operating profit to be 77.3 billion yen and net profit attributable to owners of the parent to be 48.6 billion yen.

Given the dividend policy and earnings forecast of the fiscal year under review, the Company has revised its year-end dividend forecast from 11 yen to 19 yen per share, thus making the annual dividend, including an interim dividend, 28 yen per share.

2. Details of the Revision

	Dividend per share		
	Interim	Year-end	Full Year
Previous Forecast (announced on Jan. 31, 2019)	—	¥11.00	¥20.00
Revised Forecast	—	¥19.00	¥28.00
Actual amount for the current fiscal year	¥9.00	—	—
Actual amount for the previous fiscal year (year ended March, 2018)	¥9.00	¥19.00	¥28.00

Disclaimer Regarding Forward-looking Statements

The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the day of this release,

which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this release, due to a number of factors.

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)